
The shares rose in the latest session, while Zacks’ forecasts point to a loss in the upcoming report and full fiscal year.
Viking Therapeutics closed at $32.74, up 2.92% from the previous session. The S&P 500 fell 0.25%, the Dow lost 0.86%, and the Nasdaq gained 0.24%.
Over the previous month, the shares fell 5.52%. That decline was steeper than the medical sector’s 1.01% loss and the S&P 500’s 0.42% drop.
Investors are awaiting Viking’s next financial results. Zacks projects a loss of $1 per share, which would be a 23.46% decline from the year-earlier period.
For the full fiscal year, Zacks consensus estimates call for a loss of $4.47 per share and revenue of $0 million. Those figures represent changes of -40.13% and 0%, respectively, from the prior year.
Zacks said the consensus earnings-per-share estimate has not changed over the past month. The projections are estimates, not reported results.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.